Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vascular Biogen. Ord (VBLT)

Vascular Biogen. Ord (VBLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vascular Biogen. Ord 8 HASATAT STREET MODI`IN L3 7178106 ISR

www.vblrx.com P: 972-8993-5000 F: 972-899-3500

Description:

Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.

Key Statistics

Overview:

Market Capitalization, $K 12,112
Enterprise Value, $K -5,918
Shares Outstanding, K 77,640
Annual Sales, $ 660 K
Annual Net Income, $ -32,300 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -870 K
EBIT, $ -15,880 K
EBITDA, $ -14,820 K
60-Month Beta 0.76
% of Insider Shareholders 6.13%
% of Institutional Shareholders 0.96%
Float, K 72,881
% Float 93.87%
Short Volume Ratio 0.55

Growth:

1-Year Return 19.08%
3-Year Return -86.55%
5-Year Return -88.18%
5-Year Revenue Growth -95.24%
5-Year Earnings Growth -13.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 08/14/23
Next Earnings Date 11/13/23
Earnings Per Share ttm -0.21
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 91.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-35 on 10/17/23

VBLT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -73.45%
Return-on-Assets % -54.11%
Profit Margin % -4,893.94%
Debt/Equity 0.00
Price/Sales 20.18
Price/Cash Flow N/A
Price/Book 0.57
Book Value/Share 0.28
Interest Coverage -357.89
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar